89 results about "Psa antigen" patented technology

The invention relates to a nanotechnology-based trace protein detection method, which combines enzyme-linked immunosorbent assay technology, tyramine signal amplification technology and the aggregation phenomenon of gold nanoparticles modified by different biological molecules, so an experimental method used for detecting trace proteins such as prostate specific antigen (PSA) and the like is established. The method comprises the following steps of: fixing an antibody aiming at the protein to be detected (such as the PSA) on the surface of a substrate; incubating another antibody with horseradish peroxidase (HRP) activity of the protein to be detected (such as the PSA) after capturing the protein to be detected in a sample, wherein the HRP catalyzes biotin-tyramide to generate biotin deposition under certain conditions; further amplifying a signal by using the aggregation phenomenon of the gold nanoparticles modified by biotin-labeled DNA and the gold nanoparticles modified by streptavidin; performing silver staining; and performing data analysis on an experimental result by using software. The method has the advantages of extremely low detection limit, wider detection range, capacity of detecting the antigen in a rabbit serum with complex compositions, and important application prospect.

Certain sequence variants have been found to be useful for correcting Prostate Specific Antigen levels in humans. The invention provides diagnostic applications based on such correction, including methods of diagnosis of prostate cancer.

Replication-competent adenovirus vectors specific for cells which allow a probasin transcriptional response element (PB-TRE) to function, such as cells which express the androgen receptor (AR), and methods of use of such viruses are provided. These viruses comprise an adenoviral gene under control of a transcriptional regulatory portion of a PB-TRE, which is in turn dependent upon AR expression. The gene can be, for example, a gene required for viral replication or the adenovirus death protein gene (ADP). The viruses can also comprise at least one additional adenoviral gene under control of at least one additional prostate-specific transcriptional response element, such as that controlling prostate-specific antigen expression (PSA-TRE). Thus, virus replication can be restricted to target cells exhibiting prostate-specific gene expression, particularly prostate carcinoma cells.

The invention relates to an antigen detection method and application thereof. The method converts detection of an antigen signal into detection of a nucleic acid barcode label, and comprises the following operation steps: (1) labeling modified nano magnetic microspheres by using an antibody I of an antigen to be detected to prepare immune magnetic microspheres, and labeling nano-gold sol by using an antibody II of the antigen to be detected and a nucleic acid barcode fragment at the same time to prepare a double-labeled nano-gold probe; (2) fully combining the immune magnetic microspheres, the nano-gold probe and the antigen to be detected, removing combined aggregate, and leaving supernatant fluid for detection; and (3) detecting the nucleic acid barcode label in the supernatant fluid. The antigen detection method can be applied to the detection of clinical PSA antigen. The method has the advantages of simple operation, high sensitivity, good specificity, easy automation and wide application prospect.

The recombinant protein vaccine is a fusion protein formed from connection of BCG vaccine heat shock protein 65 with 1-5 copies of human prostatic specific antigen cytotoxin T lymphocyte polyepitope,in which the single-copy polypeptide of said human prostatic specific antigen cytotoxin T lymphocyte polyepitope possesses amino acid sequence showed by SEQ ID NO:2, and the double single-copy polypeptide of the human prostatic specific antigen dcytotoxin T lymphocyte polyeptope possesses amino acid sequence showed by SEQ ID NO:4. After it is applied in human body, it can effectively prevent and cure carcinoma of prostate. Said invention also provides the gene for coding said two kinds of recombinant protein vaccines.

The invention relates to a surface enhanced Raman scattering technology-based composite material and a preparation method thereof. The composite material comprises microspheres modified with first target molecules on the surfaces and a second component modified with Raman signal molecules and second target molecule-modified polymers on the surface. In a solution containing a substance to be detected, the substance to be detected, the microspheres and the second component are bonded to the second target molecules through the first target molecules so that the composite material which can be easily precipitated through centrifugation is obtained. The invention also discloses the preparation method and a use of the composite material. The composite material can be used for detecting a human prostate-specific antigen (PSA), a human ferrohemoglobin (Hb), a procalcitonin (PCT) or disease markers (such as tumor markers, cardiovascular disease markers, senile dementia markers, mycoplasma and chlamydia), can effectively reduce false positive and false negative effects and has advantages of high sensitivity, simpleness, fastness and low cost.

A nanoplasmonic resonator (NPR) comprising a metallic nanodisk with alternating shielding layer(s), having a tagged biomolecule conjugated or tethered to the surface of the nanoplasmonic resonator for highly sensitive measurement of enzymatic activity. NPRs enhance Raman signals in a highly reproducible manner, enabling fast detection of protease and enzyme activity, such as Prostate Specific Antigen (paPSA), in real-time, at picomolar sensitivity levels. Experiments on extracellular fluid (ECF) from paPSA-positive cells demonstrate specific detection in a complex bio-fluid background in real-time single-step detection in very small sample volumes.

The present invention provides a method and device for detecting and quantifying the concentration of magnetic-responsive micro-beads dispersed in a liquid sample. Also provided is a method and microfluidic immunoassay pScreen™ device for detecting and quantifying the concentration of an analyte in a sample medium by using antigen-specific antibody-coated magnetic-responsive micro-beads. The methods and devices of the present invention have broad applications for point-of-care diagnostics by allowing quantification of a large variety of analytes, such as proteins, protein fragments, antigens, antibodies, antibody fragments, peptides, RNA, RNA fragments, functionalized magnetic micro-beads specific to CD⁴⁺, CD⁸⁺ cells, malaria-infected red blood cells, cancer cells, cancer biomarkers such as prostate specific antigen and other cancer biomarkers, viruses, bacteria, and other pathogenic agents, with the sensitivity, specificity and accuracy of bench-top laboratory-based assays.

Systems and methods for diagnosing prostate cancer. Image sets (e.g., MRI collected at one or more b-values) and biological values (e.g., prostate specific antigen (PSA)) have features extracted and integrated to produce a diagnosis of prostate cancer. The image sets are analyzed primarily in three steps: (1) segmentation, (2) feature extraction, smoothing, and normalization, and (3) classification. The biological values are analyzed primarily in two steps: (1) feature extraction and (2) classification. Each analysis results in diagnostic probabilities, which are then combined to pass through an additional classification stage. The end result is a more accurate diagnosis of prostate cancer.

The invention provides a preparation method of an electrochemical immunosensor for detecting prostate specific antigen. The method comprises the following steps of polishing a glassy carbon electrodeinto a mirror surface by using Al2O3 polishing powder, and ultrasonically cleaning; orderly dropwise adding gold nanoparticle-loaded black phosphorus nanosheet nanocomposite dispersion liquid, prostate specific antibody, ovalbumin solution, a prostate specific antigen solution and Ab2 bioprobe conjugate on the surface of the glassy carbon electrode, and flushing the electrode surface by using a phosphate buffer solution with the pH value of 7.2, thereby preparing a sandwich type electrochemical immunosensor for detecting the prostate specific antigen. The prepared electrochemical immunosensorfor detecting prostate specific antigen disclosed by the invention has the advantages of being high in sensitivity, wide in detection range, fast in detection speed, low in detection limit and convenient to operate.

The present invention relates to a kit and method for diagnosing prostate cancer, which use an antibody to prostate-specific antigen (PSA) to detect PSA in human urine. More specifically, the invention relates to a kit for diagnosing prostate cancer, which comprises an antibody to PSA and uses human urine as a sample, and to a method for diagnosing prostate cancer, which comprises brining a human urine sample into contact with an antibody to PSA in order to detect PSA in the sample.

The present invention provides a method for detecting a glycan structure of a prostate specific antigen (PSA) rapidly and with high sensitivity and determining prostate carcinoma based on the difference in the structure, in particular, a method for determining between prostate carcinoma and benign prostatic hyperplasia accurately. A method for determining prostate carcinoma, wherein the method includes a step of analyzing a PSA glycan structure in a sample derived from a test subject, and prostate carcinoma is determined in the case that amount of a glycan having LacdiNAc (N-acetylgalactosamine-N-acetylglucosamine) (LacdiNAc(+)) is more than 30% of amount of a glycan not having LacdiNAc but having LacNAc (galacotose-N-acetylglucosamine) (LacdiNAc(−)). Especially, a method for determining prostate carcinoma, wherein prostate carcinoma is determined in the case that amount of a glycan having LacdiNAc (N-acetylgalactosamine-N-acetylglucosamine) (LacdiNAc(+)) is more than 30% of amount of a glycan not having LacdiNAc but having LacNAc (galacotose-N-acetylglucosamine) (LacdiNAc(−)), and benign prostatic hyperplasia is determined in the case of 30% or less.

The invention relates to the field of immunoassay medicine, and specifically provides a chemiluminescence immunoassay diagnostic kit for a free prostate specific antigen (fPSA) and a preparation method thereof. The kit provided by the invention comprises an anti-FITC antibody coated solid phase vector, an FITC marked anti-PSA antibody, an enzyme marked anti-fPSA antibody, a chemiluminescent substrate acted by the above enzyme, a negative control solution and a positive control solution. The preparation method of the above kit comprises the following steps: 1) coating a solid-phase vector with the anti-FITC antibody; 2) marking the anti-PSA antibody with FITC to obtain the FITC marked anti-PSA antibody; 3) marking the anti-PSA antibody with an enzyme to obtain the enzyme marked anti-fPSA antibody; and 4) subpackaging and assembling. The kit provided by the invention has low cost and high sensitivity, and can improve sensitivity and reproducibility of the assay and reduce the usage amount of antibodies compared with an existing chemiluminescence immunoassay detection method.

The invention relates to a preparation method of an electro-chemiluminescence immunosensor based on silver-hybridized bismuth sulfide and belongs to the field of electro-chemiluminescence sensors. With cerium dioxide as an electro-chemiluminescence signal source, supporting quantity of an antibody can be increased by means of excellent biocompatibility and large specific surface area of gold-hybridized aminated graphene. With the silver-hybridized bismuth sulfide as a second antibody marker, detection on a prostate specific antigen is achieved according to different electro-chemiluminescence signal intensity of to-be-detected substance in different concentrations.

The invention discloses a preparation method of a cathode photoelectric immunosensor of cyclometalated iridium complex sensitized NiO for detecting a prostate specific antigen. The preparation methodcomprises the following steps: firstly, preparing a nano porous NiO film on an ITO electrode by adopting a hydrothermal synthesis method; then fixing a photosensitizer [Ir(C6)2(dcbpy)]<+>PF6<-> (wherein C6 is coumarin 6 and dcbpy is 2,2'-dipyridine-4,4'-dicarboxylic acid) on the surface of the nano NiO film through a condensation effect; and the prostate specific antigen capture antibody is covalently modified on the electrode by virtue of chitosan and glutaraldehyde to prepare the sensing working electrode. Through the specific immune reaction between the prostate specific antigen and the antibody thereof, the detection of the concentration of the prostate specific antigen is realized, and the kit has high sensitivity and high specificity.

The invention relates to the medical field of immunoassay, and specifically, the invention innovatively designs a prostate-specific antigen detection kit based on second antibody modified shear enzyme initiated DNA molecular machine cycle amplification. The kit provided by the invention includes: an anti-PSA antibody coated solid phase carrier, a shear enzyme labeled anti-fPSA antibody, a reaction solution (DNA molecular machine) on which the shear enzyme acts, and a negative control solution and a positive control solution. The kit provided by the invention has high sensitivity, and compared with the existing optical immunoassay detection method, can improve the analysis sensitivity and reproducibility, and reduce the antibody dosage.

Chemical conjugates which comprise oligopeptides, having amino acid sequences that are selectively proteolytically cleaved by free prostate specific antigen (PSA) and known cytotoxic agents are disclosed. The conjugates of the invention are characterized by attachment of the cleavable oligopeptide to the oxygen atom at the 4-position on a vinca drug that has be desacetylated. Such conjugates are useful in the treatment of prostatic cancer and benign prostatic hypertrophy (BPH).